溶血尿毒综合征 中国就医指南

Hemolytic Uremic Syndrome (HUS) is a life-threatening thrombotic microangiopathy characterized by the triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. It results from endothelial damage in small vessels—particularly in the renal glomeruli—triggering platelet activation, fibrin deposition, and mechanical destruction of red blood cells. The most common form, typical HUS (tHUS), is predominantly post-infectious, frequently associated with Shiga toxin–producing Escherichia coli (STEC), especially serotype O157:H7, following diarrheal illness. Atypical HUS (aHUS), accounting for ~5–10% of cases, arises from dysregulation of the alternative complement pathway due to genetic mutations (e.g., in CFH, CFI, MCP, C3, or THBD) or autoantibodies, leading to uncontrolled complement-mediated endothelial injury independent of infection. Less common triggers include medications (e.g., calcineurin inhibitors, quinine), malignancies, autoimmune disorders, pregnancy, and HIV. Epidemiologically, HUS has an annual incidence of approximately 2–3 cases per 100,000 children in developed countries, with peak onset between ages 6 months and 4 years; adult-onset HUS is rarer but carries higher mortality and greater risk of chronic kidney disease. Risk factors include young age (for STEC-HUS), inherited complement abnormalities (for aHUS), immunosuppression, and certain geographic exposures (e.g., undercooked beef, contaminated water). Beyond acute morbidity—including seizures, stroke, pancreatitis, and cardiac complications—HUS profoundly impacts long-term quality of life: up to 25% of survivors develop persistent hypertension, 10–20% progress to end-stage kidney disease requiring dialysis or transplantation, and many experience neurocognitive deficits, fatigue, anxiety, and reduced physical functioning. Children may face school absenteeism, developmental delays, and psychosocial stress; adults often confront employment limitations, financial strain from recurrent care, and diminished health-related quality of life scores across physical, emotional, and social domains. Early recognition—especially of oliguria, pallor, petechiae, lethargy, and bloody diarrhea—is critical. Diagnosis relies on peripheral blood smear (schistocytes), low haptoglobin, elevated LDH, decreased platelets, elevated creatinine, and absence of other causes (e.g., TTP, DIC). Complement genetic testing and anti-CFH antibody assays are essential in suspected aHUS. Without timely intervention, mortality can exceed 10% in severe cases, particularly with neurological involvement or multiorgan failure.

# 溶血尿毒综合征（HUS）治疗方案与费用明细（肾内科）

一、非手术/保守治疗方案

适用人群：典型HUS（如大肠杆菌感染相关）、早期肾功能轻度受损（eGFR >30 mL/min/1.73m²）、无严重神经系统并发症者。

• •支持治疗：水化、电解质纠正、高血压控制（ACEI/ARB类）——¥800–2,500/周
• •血浆置换（PEX）：每日1次，持续5–10天；含血浆分离+新鲜冰冻血浆输注——¥3,200–4,800/次（含血浆费¥1,600–2,200）
• •必要检查费：外周血涂片+LDH+Haptoglobin+ADAMTS13活性+补体B因子/C3/C5b-9检测——¥1,800–3,000/套

二、核心介入/替代治疗方案

适用人群：急性肾损伤需透析、eGFR <15 mL/min/1.73m²、顽固性微血管病溶血者。

• •连续性肾脏替代治疗（CRRT）：72小时起，含抗凝管理及滤器耗材——¥4,500–6,800/天
• •紧急血液透析（HD）：每周3次，含导管置入+透析液+肝素——¥1,200–1,800/次
• •术前检查（含CRRT/HD评估）：心脏超声+凝血四项+血培养+中心静脉置管超声引导——¥2,100–3,300

三、特殊复杂/晚期方案

适用人群：非典型HUS（aHUS）、ADAMTS13正常但补体旁路异常激活、耐药性复发或进展至终末期肾病（ESRD）。

• •依库珠单抗（C5抑制剂）：首剂负荷+维持治疗（每14天1次），按体重计费——¥28,000–42,000/支（年均约¥35万–52万元）
• •肾移植联合补体抑制：术前基因检测（CFH/CFI/MCP等）+术后长期依库珠单抗——总费用¥45万–70万元（含手术¥18万–25万、免疫抑制剂¥2.5万/年）

四、方案快速选择指南

• •预算有限（<¥5万）：首选血浆置换+支持治疗（典型HUS）
• •中等预算（¥5–25万）：CRRT+补体检测+个体化PEX疗程
• •高需求/耐药/遗传性aHUS：依库珠单抗启动+多学科随访（肾内科+遗传咨询）